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Abstract
The small Ca-binding protein, S100A4, has a well-established metastasis-promoting activity. Moreover, its expression
is tightly correlated with poor prognosis in patients with numerous types of cancer. Mechanistically, the extracellular
S100A4 drives metastasis by affecting the tumor microenvironment, making it an attractive target for anti-cancer ther-
apy. In this study, we produced a function-blocking anti-S100A4 monoclonal antibody with metastasis-suppressing
activity. Antibody treatment significantly reduced metastatic burden in the lungs of experimental animals by blocking
the recruitment of T cells to the site of the primary tumor. In vitro studies demonstrated that this antibody efficiently
reduced the invasion of T cells in a fibroblast monolayer. Moreover, it was capable of suppressing the invasive growth
of human and mouse fibroblasts. We presume therefore that the antibody exerts its activity by suppressing stroma
cell recruitment to the site of the growing tumor. Our epitope mapping studies suggested that the antibody recogni-
tion site overlaps with the target binding interface of human S100A4.We conclude here that this antibody could serve
as a solid basis for development of an efficient anti-metastatic therapy.
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Introduction
More than 90% of cancer-related deaths are caused by dissemination
of cancer cells to distant organs with subsequent formation of second-
ary tumors, known as metastases. Metastatic dissemination of cancer
cells in the body occurs through interaction with cancer-associated
stroma cells that play a crucial role in stimulation of cancer cell dis-
semination, survival, and colonization of secondary organs [1]. In
contrast to the primary tumor, metastasis is especially challenging
to treat because of its systemic nature and frequent association with
resistance to existing therapeutic agents [2]. Despite substantial prog-
ress in targeted cancer treatments, development of a therapy, which
specifically targets molecules of the metastatic process, is still at a very
early stage. However, progress in identification of molecules involved
in metastasis has helped to identify new targets, thereby creating novel
opportunities to prevent or treat metastasis.
Recently, the metastasis-promoting S100A4 protein was suggested
as a therapeutic target to prevent metastasis [3]. S100A4 belongs to
the S100 family of small Ca-binding proteins. It plays a regulatory
role in a variety of cellular processes, such as cell motility and differ-
entiation [4]. In clinic, S100A4 has gained attention because of its
up-regulation in different types of human cancers, which has been cor-
related to a bad prognosis for patients (reviewed in [5]).
Numerous experimental approaches, including studies of xeno-
graft and genetically modified mouse models, have verified a causal
role of S100A4 in promoting metastatic disease (reviewed in [5,6]).
Mechanistically, metastasis-stimulating activity could be attributed to
different extracellular and intracellular functions of the S100A4 pro-
tein. For instance, S100A4 stimulates cancer cell motility and inva-
sion through interaction with intracellular targets such as nonmuscle
myosin [7–9]. As an extracellular protein, S100A4 affects different
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signaling pathways. It has been shown that S100A4 modulates epider-
mal growth factor receptor signaling by interacting with epidermal
growth factor receptor ligands [10] and activates mitogen-activated pro-
tein (MAP) kinase and nuclear factor kappa-light chain-enhancer of
activated B-cells (NF-κB) pathways in a variety of cell types [11,12].
Downstream, the S100A4-dependent activation leads to the remodel-
ing of the extracellular matrix, induces angiogenesis, and attracts differ-
ent immune cells to the growing tumor [13–16].
Accumulated data suggested that S100A4 is an attractive candidate
for anti-metastatic therapy. Analysis of the tumor secretome revealed that
S100A4 is accumulated in human breast tumor microenvironment [17].
Similarly, increased levels of S100A4 were detected in early stage tumors
in a spontaneous metastatic mouse mammary cancer model [16].
The potential efficiency of S100A4 as a therapeutic target was
demonstrated by suppression of metastasis in S100A4-deficient mice,
which was associated with aberrant stroma development, in particular
deficiency in T cell accumulation [16,18,19]. Recently, an inhibitor
of S100A4 transcription, niclosamide, was identified as a suppressor
of metastasis formation in a colon cancer xenograft model [20].
Among prospective biologically targeted therapies, antibody-based
therapies are regarded as a mainstream of the future cancer treatment
strategy [21,22]. Compared with traditional treatment options, an
antibody-targeted therapy is more specific, less toxic, and may be more
effective [23,24].
In the present work, we generated and selected an anti-S100A4–
neutralizing antibody with the purpose of blocking metastasis for-
mation. The selected anti-S100A4 antibody efficiently recognized
mouse and human S100A4 protein and blocked metastasis formation
in a mouse xenograft model. The antibody was proficient in blocking
not only the invasion of mouse and human fibroblasts but also the
attraction of mouse T cells to the fibroblast monolayer, indicating that
the metastasis-neutralizing activity of this antibody is associated with
prevention of stroma cell invasion of the primary tumor.
Materials and Methods
Cell Lines
The CSML100 mouse mammary adenocarcinoma cell line was
derived from spontaneous tumors in A/Sn mice [25]. Isolation of
mouse embryo fibroblast (MEF) cell lines has been described earlier
[19]. All other cells were obtained from the American Type Culture
Collection (ATTC) collection. Cell lines were propagated in a suit-
able basal medium (Gibco BRL) supplemented with 10% FBS (Life
Technology LTD, Paisley, United Kingdom), penicillin (100 units/ml),
and streptomycin (100 units/ml) in a humidified 5% CO2 atmosphere.
Mice
A/Sn strain of mice was used in all mouse experiments. All animals
were maintained according to the Federation of European Laboratory
Animal Science Associations guidelines for the care and use of labo-
ratory animals.
Peptides
The following nine 10- to 12-mer peptides corresponding to the
entire 101 amino acids of human S100A4 protein were synthesized by
solid-phase synthesis (Alpha Diagnostic International, San Antonio,
TX) and used for epitope mapping by ELISA and in inhibition experi-
ments: #1: MACPLEKALD (10-mer: 1–10), #2: VMVSTFHKYS
(10-mer: 11–20), #3: GKEGDKFKLNK (11-mer: 21–31), #4:
SELKELLTREL (11-mer: 32–42), #5: PSFLGKRTDEA (11-mer:
43–53), #6: AFQKLMSNLDSN (12-mer: 54–65), #7: RDNEVDF-
QEYCV (12-mer: 66–77), #8: FLSCIAMMCNEF (12-mer: 78–89),
#9: FEGFPDKQPRKK (12-mer: 90–101).
Enzyme-linked Immunosorbent Assay
ELISA was performed as described by Kosmac et al. [26]. The con-
centrations of peptides for coating were between 0.1 and 1000 nM.
Serial dilutions of the monoclonal antibody (mAb) ranged from 0.032
to 32 nM. The absorbance was quantified spectrophotometrically
at 405 nm using a VersaMax microplate reader (Molecular Devices,
Sunnyvale, CA).
Western Blot
Western blot was performed as described by Klingelhöfer et al.
[10]. Mouse monoclonal anti-S100A4 antibodies (3B1C4, 11F8.3,
and 6B12, all IgG1κ isotypes) or polyclonal rabbit anti-S100A4 pro-
duced in our laboratory were used as primary antibodies. As secondary
antibodies, rabbit anti-mouse HRP-conjugated or goat anti-rabbit
HRP-conjugated antibodies were used. Both antibodies were obtained
from Dako (Glostrup, Denmark).
To detect endogenous S100A4 protein from different cell lines, 0.4 ×
105 cells per well were seeded on a six-well tissue culture plate and grown
until the cells reached confluence under standard tissue culture condi-
tions. Protein extracts were made by lysing cells in 300 μl of 1× sodium
dodecyl sulfate–gel loading buffer and subsequent boiling at 95°C for
5 minutes. Twenty microliters of cell extract were loaded per lane.
Pull-down and Peptide Competition Experiments
For peptide competition experiments, 1 μg of antibody was pre-
incubated with 250 ng of peptides in the interaction buffer [TBS,
0.1 mM CaCl2, 0.5% blocking solution (Roche Diagnostics A/S,
Hvidovre, Denmark)] for 1 hour at room temperature, followed by
1-hour incubation with 250 ng of recombinant S100A4. The anti-
bodies were pulled down with 0.05 mg of Pierce Protein A/G magnetic
beads (Thermo Scientific, Slangerup, Denmark) for 30 minutes followed
by washing in TBS/0.05% Tween-20. The amount of co-precipitated
S100A4 was analyzed by Western blot.
For the target binding site competition experiment, 500 ng of
S100A4 was pre-incubated with a C-terminal fragment of p53 or the
p53Δ1 in 2.5- and 10-fold molar excess in the interaction buffer for
1 hour at room temperature followed by addition of 2 μg of 6B12 mAb
for 1 hour. The pull-down was performed as described for the peptide
competition experiment.
T-lymphocyte Invasion Assay
Invasion of primary mouse T lymphocytes into fibroblast mono-
layers was tested using a modification of methods described else-
where [16,27]. MEFs were grown to confluency in 12-well plates;
T lymphocytes were labeled with Vybrant DID cell-labeling solution
(Life Technology LTD) according to the manufacturer’s instructions.
Labeled T lymphocytes (4.5 × 105) were added to the wells and in-
cubated for 2 hours. Noninvaded cells were removed by washing and
mechanical agitation three times in phosphate-buffered saline. The in-
filtrated cells were counted using a fluorescence microscope in 10 random
fields (original magnification, ×100). Invasion assays were performed in
RPMI 1640 containing 10% fetal calf serum with or without 6 μg/ml
rabbit IgG (Sigma-Aldrich, St Louis, MO) or 6 μg/ml 6B12 antibodies.
The experiments were performed in quadruplicate and repeated three times.
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Three-dimensional Matrigel Invasion Assay
Detailed protocol for invasion assay in three-dimensional (3D)
Matrigel is described elsewhere [28]. Briefly, 6 × 104 cells were in-
cubated in a hanging drop of medium to form an aggregate, which
was then placed on a layer of Matrigel containing Dulbecco’s modified
Eagle’s medium and 10% fetal calf serum. The clump was covered with
a drop of Matrigel and incubated at 37°C for polymerization. Invasive
growth was stimulated by addition of conditioned medium from cancer
cells with or without S100A4. Extent of the outgrowth was monitored
in an inverted microscope using ×10 objective for 120 hours.
Immunofluorescence and Immunohistochemical Analyses
Tumor tissue sections were stained with affinity-purified rabbit
polyclonal antibodies against CD3 (Abcam, Cambridge, United
Kingdom) and rat mAbs against CD31 (clone MEC 13.3; BD
Biosciences, Albertslund, Denmark), as described elsewhere and ac-
cording to the manufacturer’s protocols [16]. For immunofluorescence
staining, MEF−/− or MEF+/+ were grown overnight on an eight-
chambered glass coverslip (Greiner Bio-One, Frickenhausen, Germany),
fixed, and stained as described earlier by Olsen et al. [29].
Animal Experiments
A/Sn mice were subcutaneously injected with 1 × 106 CSML100
cells in a volume of 200 μl/mouse, and on the same day, the loading
dose (7.5 mg/kg in a volume of 100 μl) of antibodies was injected
intraperitoneally. Injections of antibodies were repeated three times a
week. The animals were sacrificed when the first tumor reached the
maximal allowed size (1 cm3) by an intraperitoneal injection of pen-
tobarbital (Euthanyl) followed by perfusion with phosphate-buffered
saline. The tumor tissue and lungs were paraffin-embedded, sectioned
Figure 1. The specificity of 6B12 mAb. (A) 6B12 mAb recognizes mouse and human S100A4 proteins and shows no cross-reactivity
to other S100 family members as shown by Western blot analysis. Lower panel amido black staining of the polyvinylidene difluoride
(PVDF) membrane is serving as a loading control. (B) Immunofluorescence staining of MEF(+/+) and MEF(−/−) using 6B12 antibody
(green). F-actin is stained by rhodamine-phalloidin (red) and the nucleus by 4′,6-diamidino-2-phenylindole (DAPI, blue). (C) Western blot
analysis membrane stained with 6B12mAb comparing cell extract fromMEF(+/+) and MEF(−/−) cells. Coomassie blue staining and α-tubulin
serve as loading controls. (D and E) Detection of endogenous S100A4 protein by 6B12 mAb from cell extracts of mouse and human
cancer cell lines: mouse mammary adenocarcinoma, 4T1 and CSML100; human breast cancer, MCF7, MDA-MB-231, MDA-MB-468, T-47D;
human colon cancer, SW-480, SW-620, colo205, LoVo, HT-29.
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(4 μm), and stained with hematoxylin and eosin. The total metastatic
burden was quantified by calculating the percentage area of each lung
section occupied by metastases as described elsewhere [16].
Statistical and Computerized Analyses
Data are presented as average ± SEM. The confidence level was calcu-
lated using Student’s t distribution. For the prediction of nonsolvent–
exposed amino acids of S100A4, we used the Epitopia server (http://
epitopia.tau.ac.il/index.html) [30]. As input sequence, we used the
calcium-bound dimeric human S100A4 (PDB ID: 2Q91) [31]. Anal-
yses and imaging were performed with the Molegro Molecular Viewer
software v. 2.2.0/mac (Molegro ApS, Aahus, Denmark).
Results
Production and Characterization of a Panel of
S100A4-specific mAbs
Recent data have indicated that S100A4 promotes metastasis via
modulating host immune cells [15,16]. This limited us to testing the
anti-metastatic efficiency of S100A4-neutralizing antibody in immuno-
competent mice. Furthermore, to obtain a function-neutralizing
antibody with the prospective to develop a humanized antibody for
therapeutic use, we selected antibodies that recognized both human
and mouse proteins. We used recombinant mouse S100A4 protein
for screening the hybridoma clones to identify and select only those
hybridomas that produce antibodies of appropriate specificity. From
this panel of S100A4-specific antibodies, three mAbs (3B1C4, 11F8.3,
and 6B12) with the highest affinity in the ELISA screen were selected
(data not shown).
First, we used a Western blot assay to test whether the antibodies
recognize human S100A4 protein or cross-react with other members
of the S100 family. As shown in Figure 1A, 3B1C4 and 6B12 mAbs
recognized both mouse and human S100A4 proteins, whereas 11F8.1
only reacted with the mouse protein. Importantly, all three antibodies
showed no cross-reactivity to other S100 family members.
Second, immunocytochemical analysis showed that all three anti-
bodies detected S100A4 protein expressed in MEFs. S100A4 immuno-
reactivity was observed in the cytoplasm in the perinuclear area with
similar distribution as reported previously [32]. S100A4(−/−) MEFs,
which served as a negative control, showed no immunofluorescence
staining and revealed no cross-reactivity (Figure 1B). We then tested the
recognition of S100A4 protein in total cell extracts from S100A4(+/+)
and S100A4(−/−) MEFs as well as from human and mouse cancer cell
lines (Figure 1, C and D). Data in Figure 1A show that 11F8.3 anti-
body recognized only the mouse protein, whereas the two other anti-
bodies were able to recognize both mouse and human S100A4. In
contrast to the other clones, 3B1C1 also recognized some unidentified
proteins with an approximate size of 55 and 90 kDa. This cross-
reactivity makes the 3B1C1 antibody less prospective. Finally, 6B12
mAb also recognized S100A4 in a panel of human cancer cell lines
from breast cancer, MDA-MB-468, as well as from various human
colon cancers (Figure 1E).
Figure 2. In vitro blocking activity of 6B12 mAb. (A) Representative phase-contrast images of fibroblasts invading the Matrigel in re-
sponse to conditioned media from VMR mouse adenocarcinoma cells alone, after addition of S100A4 (1 μg/ml) or in the presence
of S100A4-neutralizing mAb 6B12 (8 μg/ml) after 48 hours of incubation. (B) 6B12 mAb inhibits significantly the invasion of mouse
fibroblasts and (C) in the presence of MCF7 breast carcinoma cell conditioned media HMF3s under 3D culture conditions (P = .0274
and P = .0400, respectively).
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Evaluation of the Function-Blocking Capability of Different
Anti-S100A4 Antibodies
Because the purpose of this study was to isolate an antibody with
metastasis-blocking activity, we decided to perform preliminary anal-
yses, including in vitro and in vivo assays. The in vitro assay was based
on the ability of the S100A4 protein to stimulate cell invasion in a
3D Matrigel [33]. As shown in Figure 2A, the addition of S100A4
stimulated the invasion of MEF(+/+) into the matrix. 6B12 Antibody
added to the culture medium successfully blocked the invasion
(Figure 2A, left panel). The blocking ability of the antibodies was mea-
sured by semiquantitative assessment of the extent of the invasion.
11F83 Antibody was not able to block the S100A4-stimulated in-
vasion of fibroblasts into the Matrigel (Figure 2B), 6B12 and 3B1C4
mAbs blocked the invasion to a similar extent. Because we were inter-
ested in selection of a metastasis-blocking antibody applicable for
human cancer, we further analyzed the ability of 6B12 antibody to
block invasion of human mammary fibroblasts (HMF3s). Figure 2C
shows that 6B12 antibody blocked the invasion of HMF3 cells (P =
.04), indicating that it is equally efficient in blocking the physiological
activity of both human and mouse proteins.
We further characterized antibodies by their ability to neutralize
metastasis-stimulating activity of the S100A4 protein in vivo. The
ability of the three antibodies to block tumor growth and metastasis
formation by the CSML100 cell line was tested in a spontaneous me-
tastasis assay [25]. This assay allowed us to test changes both in tumor
growth and metastasis formation. At the end of the experiment, the
average tumor size showed no statistically significant differences be-
tween different groups (Table 1). The treatment did not show signs
of toxicity, as the mean body weight showed only a marginal, less than
3%, difference (Table 1). The assessment of the metastatic burden in
the lungs of mice treated with the three antibodies, however, exhib-
ited substantial relative difference. Mice treated with 11F8.3 antibody
showed the highest metastatic burden, indicating that the antibody
was not efficient. This result corroborates the findings of the invasion
assay analysis, which showed inability of 11F3 to block invasion
(Figure 2B). 3B1C4 Antibody showed only a weak tendency in
metastasis-neutralizing activity (Table 1), whereas 6B12 antibody
substantially suppressed metastasis. Comparison of the 6B12- and
the 11F8.3-treated groups displayed a 10-fold lower metastatic burden,
although this difference was not statistically significant (P = .052). In
summary and on the basis of these results, 6B12 mAb was chosen for a
more detailed study.
Anti-S100A4 mAb Significantly Reduces the Metastatic
Burden in Lungs and Suppresses T Cell Accumulation
in Primary Tumor
On the basis of the strong tendency of 6b12 mAb to suppress
metastasis and the small number of animals used in the pilot study,
we decided to perform a large-scale mouse experiment to assess in
detail the metastasis-suppressing activity of the antibody. Following
the same experimental setup as the previous experiment, the anti-
bodies were injected intraperitoneally into mice grafted with CSML100
cells. Similar to the previous experiment, the extent of tumor growth
of the 6B12 mAb–treated group did not substantially differ from the
control group (Figure 3A). Autopsy analysis revealed that the overall
amount of metastasis-free animals was more than two times higher in
the 6B12-treated group (45%) than in the control (19%). Moreover,
assessment of the metastatic burden in lung tissue sections showed that
this parameter was significantly (P = .02) reduced in the 6B12-treated
group (Figure 3, A and B).
We extended our studies to determine whether neutralization of
the S100A4 activity by 6B12 antibody also affected the composition
of tumor-associated stroma. Immunohistochemical staining of sec-
tions of the primary tumors with antibodies specific for endothelial
cells (CD31) and T cells (CD3) revealed that treatment with 6B12
antibody did not affect vessel density. In contrast, the amount of T
cells accumulated in the vicinity of the growing tumor was reduced
by 40% (Figure 3C ). This confirms our previous observations that
S100A4 deficiency leads to changes in the tumor stroma compart-
ment, particularly in the recruitment of immune cells to the site of
the growing tumor [16].
To further support the argument that 6B12 mAb mechanistically
acts to reduce T cell accumulation in the primary tumor, we performed
an in vitro T cell invasion assay. Previously, we have shown that
S100A4(+/+) but not S100A4(−/−) fibroblasts substantially stimulate
the ability of T cells to invade the fibroblast monolayer [16]. Using
the same approach, we demonstrate here that 6B12 antibody reduced
T cell invasion into the fibroblast monolayer by approximately 30%
(Figure 3D). This result supports our initial notion that 6B12 antibody
manifests its metastatic activity by inhibiting the recruitment of T cell
to the primary tumor site.
Determining of the Binding Site of 6B12 Antibody
To further investigate the mechanism of 6B12’s neutralizing activ-
ity, we performed an epitope mapping analysis by testing the affinity
of 6B12 antibody to nonoverlapping 10- to 12-mer peptides of the
entire human S100A4 protein with an ELISA. 6B12 Antibody binds to
peptide 7 (RDNEVDFQEYCV) and peptide 8 (FLSCIAMMCNEF)
but not to the others, as shown for peptide 9 (Figure 4A). Competitive
immunoprecipitation assay revealed that peptides 7 and 8 block the in-
teraction of 6B12 antibody with the S100A4 protein, whereas peptide 9,
chosen as a negative control, had no effect on 6B12 antibody interaction
(Figure 4B). Peptide 7 forms the second EF-hand [amino acid (aa)
63–74] for Ca2+ coordination and peptide 8 partly forms the α-helix IV
(aa 72–88) of the S100A4 protein [31].
In addition, peptides 7 and 8 contribute to the hydrophobic cleft,
which forms the S100A4 target binding interface [34]. We therefore
Table 1. Effect of Different Anti-S100A4 mAbs on Tumor Growth and Metastasis Formation.
α-S100A4 mAb 3B1C4 11F8.3 6B12
Number of mice (N ) 7 6 7
Average tumor size (mm3) 200.7 ± 39.05 230.3 ± 21.90 176.6 ± 23.91
Metastatic burden (%) 3.246 ± 1.707 4.878 ± 2.170 0.4997 ± 0.2345
Average weight loss before/after (g/g) 26.6/25.6 ≙ 3.01% 26.4/25.6 ≙ 4.55% 26.1/24.6 ≙ 5.75%
The effect of 3B1C4, 11F.8.3, and 6B12 mAbs on the tumor size, the amount of metastasis-free animals, and the metastatic burden in CSML100 xenograft mice.
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studied whether 6B12 antibody can interfere with S100A4-p53 inter-
action. To study this, we used an S100A4 pull-down assay with a p53
C-terminal fragment that contains the S100A4 binding interface [35].
As a negative control, we used the C-terminal fragment of p53 (p53Δ1)
with a 30–amino acid deletion lacking the binding site (Figure 4C ). As
shown in Figure 4D, the amount of S100A4 precipitated by 6B12mAb
was substantially reduced when the S100A4 protein was pre-incubated
with p53 C-terminal fragment, compared to the control. In contrast,
the C-terminal p53 deletion mutant (p53Δ1) did not interfere with
6B12 binding (Figure 4D). In accordance with the previous result, this
strongly suggests that the 6B12 epitope at least partially overlaps with
the target binding interface.
We next performed a computer-assisted analysis to predict the
recognition epitope on the S100A4 protein structure. We used the
published structure of calcium-bound dimeric human S100A4 in a
resolution of 1.63 Å (PDB ID: 2Q91) and the Epitopia Web server
[30]. On the basis of the data presented above, the 24 amino acid–
long sequence of peptides 7 and 8 were used as core region of the
antibody-S100A4 interface. It is worth noting that the sequences
of peptides 7 and 8 are identical in the mouse and human proteins.
Amino acids, which could not be part of the epitope surface because
they are either hidden in the protein structure or at a different planar
level, were excluded from the potential epitope (see details in
Table W1). This analysis suggests a planar structure on the surface
of S100A4 for the possible 6B12 epitope with a diameter of 30.9 Å
(Figure 4A and 5A). The surface of the planar patch is formed by
four amino acids from peptide 7 (Arg66, Asn68, Gln73, and Val77)
and seven amino acids from peptide 8 (Cys81, Ile82, Met84, Met85,
Asn87, Glu88, and Phe89; Figure 5B). The suggested epitope consists
of the following sequence: 66R-N-Q-V-CI-MM-NEF89.
Discussion
The efficacy of mAbs as cancer therapeutics has been proven in recent
years. Antibodies are used both to target surface antigens on tumor cells
and to enhance anti-tumor immune responses by targeting immune cells
[36]. Here, we report the isolation and characterization of an S100A4-
blocking antibody that exhibits a remarkable anti-metastatic effect. Even
though metastases are the most serious complication of cancer, the
success in development of anti-metastatic therapies is very limited and
mostly directed toward suppression of the primary tumor growth [21].
A number of studies carried in the last decades showed that
S100A4 plays a key role in stimulation of metastasis [37]. The exact
mechanism of its metastasis-stimulating function is not clear. Recently,
several studies suggested the extracellular form as major trigger of
Figure 3. Anti-S100A4 mAb 6B12 suppresses metastasis and inhibits T lymphocytes attraction to the tumor site. (A) Testing the effect of
6B12 mAb in a spontaneous metastasis model. The amount of metastasis-free animals in the 6B12-treated group was increased com-
pared to the control group, 45% to 19.1%. (B) Significant (P = .0197) reduction of metastatic burden in the lung of mice treated with
6B12 mAb compared to the control. (C) 6B12 mAb inhibits the attraction of T lymphocytes to the tumor site compared to the IgG-treated
control group (T cells total: 326 vs 550, P = .0003; N = 5 per group; 10 fields per tumor were analyzed). (D) S100A4 stimulated the
attraction of T lymphocytes to the fibroblast monolayer (control), which is inhibited in the presence of the neutralizing S100A4-specific
mAb 6B12; in contrast, the mouse IgG control did not display inhibiting function (P = .0231).
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metastasis formation [10,12,16,33,38], making it an easily accessible
target for therapy. Moreover, the expression pattern of S100A4 in a
normal organism is quite restricted [39,40], and mice with inactivated
S100A4 gene are viable and fertile [41].
Recently, by using high-throughput screening technology, the S100A4
transcription inhibitor, niclosamide, was identified. Consistent with its
inhibitory activity toward S100A4, niclosamide led to inhibition of
metastasis formation in a colon cancer xenograft model [20].
Figure 5. Epitope mapping revealed a planar patch on the dimer of S100A4 governing the epitope for 6B12 antibody. (A) The ribbon
diagram represents the molecular structure of the calcium-bound S100A4 dimer (2Q91). The amino acids of S100A4, which contribute
to the potential 6B12 epitope, are indicated in green (only A chain is colored). The arrow indicates the patch size in diameter (30.9 Å). The
α-helices of S100A4 are shown in red and calcium atoms are shown in orange. (B) Molecular surface visualization of S100A4 shows the
predicted epitope region located in/or close to the hydrophobic cleft for target protein interaction (arrows). The surface of the suggested
epitope is colored in green and its amino acids are labeled.
Figure 4. The epitope of 6B12 mAb is located at the C terminus of S100A4 protein overlapping with the target binding interface.
(A) ELISA showing 6B12 affinity to peptides 7 and 8 but not peptide 9 to the human S100A4 sequence. (B) The competitive immuno-
precipitation assay showing the pull-down of S100A4 by 6B12 antibody in the absence (line 1) and the presence of peptides 7, 8, and
9 (P7, P8, and P9). As control, lane 5 shows a pull-down without added 6B12 mAb. (C) Diagram of the p53 fragments, which were used
for competitive pull-down experiments. The recombinant C-terminal 100 aa of human p53 fusion construct, including a His-tag, a V5
epitope, and a TEV protease cleavage site, was used to show competition between 6B12 mAbs. Fragment p53Δ1 is partially lacking the
binding site of S100A4 (bs-S100A4). (D) Binding of the C-terminal p53 fragment to S100A4 compromises the pull-down by 6B12 mAb.
The p53 fragments were added in 2.5- and 10-fold molar excess. As control, lane 1 shows a sample without added 6B12. As positive
control, lane 2 shows a pull-down of 500 ng of human S100A4 by 6B12 mAb (2 μg).
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The purpose of the present study was to identify an anti-S100A4
mAb with metastasis-blocking activity. We also intended to reveal the
corresponding epitope. End point assessment of the anti-metastatic
activity of 6B12 antibody in a spontaneous metastasis assay showed
significant suppression of metastasis. Curiously, analysis of the dynam-
ics of tumor growth showed no difference in this parameter. This ob-
servation confirms data obtained earlier from analysis of spontaneous
mammary tumor formation in the PyMT-S100A4 knockout mouse
model [16] and once more supports the notion that S100A4 protein
is a metastasis- rather than a tumor-promoting protein.
T cell accumulation in the primary tumors of the 6B12 antibody–
treated group was substantially suppressed. A decreased accumulation of
T cells of yet an unidentified subclass was recently observed in tumors
of S100A4(−/−) PyMT double transgenic mice [16], which is in a good
agreement with the above-mentioned data. In recent years, it has been
shown that tumor-infiltrating T cells can promote tumor cell invasion,
metastasis, and aggressive behavior [42]. However, the functional sig-
nificance of leukocytes in regulating pro-tumor immunity is poorly
understood. Studies in mice demonstrated that a subpopulation of
CD4+ T lymphocytes promotes the invasion and metastasis of breast
cancer cells by inducing the ability of tumor-associated macrophages
to activate pro-tumorigenic pathway in mammary epithelial cells
[43]. Increased presence of immune cells, in particular T regulatory
cells in primary tumors, correlates with low tumor grade and poor over-
all survival of patients with breast cancer [44].
Human and mouse S100A4 sequences differ in six amino acids.
The recognition sequence of 6B12 mAb was mapped to peptides 7
and 8 of S100A4, which are identical between human and mouse.
Computer-assisted analysis of the 3D structure of human S100A4 di-
mer localized the interactive epitope to an area that is recognized as a
target binding site of S100 proteins [45]. A characteristic of this inter-
action site is a hydrophobic cleft, which has recently been shown by
crystal structure analysis to interact with a 45-residue fragment of non-
muscle myosin heavy chain IIA [46]. Previously, we have demonstrated
p53 as another target for S100A4 [35]. Here, we show that a fragment
of p53, containing the target binding site, competed with 6B12 anti-
body in binding with S100A4. Therefore, one could speculate that
interference of the antibody with target binding is the putative mech-
anism of 6B12 mAb’s blocking activity.
However, a combination of different mechanisms, documented
for other mAb therapies, cannot be excluded [21]. For instance,
binding by antibody to S100A4 in the blood and tumor micro-
environment could lead to a faster body clearance of the S100A4
molecule. Because the function-blocking antibody was tested in
immunocompetent mice, neither one can exclude innate immune
effector mechanisms that engage the Fc portion of antibodies through
Fc receptors [47]. Such mechanisms include antibody-dependent
cellular cytotoxicity and complement-mediated cytotoxicity. For in-
stance, antibody-dependent cellular cytotoxicity effects have been well
described as an accompanying cytotoxic mechanism for therapeutic
mAbs, like trastuzumab, rituximab, alemtuzumab, ofatumumab, and
cetuximamb [47–50]. 6B12Antibody could potentially provoke immuno-
logic anti-tumor effects. However, the fact that tumor development was
not affected by the antibody treatment argues against this proposition.
In summary, this work shows that a specific anti-S100A4 anti-
body, 6B12, efficiently inhibited the metastasis formation directed
by grafted tumor cells in a spontaneous metastasis assay. Identification
of the blocking epitope paves the way for development of an efficient
anti-metastatic therapy.
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Table W1. 6B12 Epitope Characterization by Computerized Analysis of the 3D Structure of
Dimeric S100A4.
Residue Helix 4-4′ Helix 1-4′ Nonsolvent Exposed/Nonplanar Suggested Epitope
Peptide 7 R 66 R 66
D 67 Nonplanar –
N 68 N 68
E 69 Nonplanar –
V 70 Nonsolvent –
D 71 Nonplanar –
F 72 F 72 Nonplanar –
Q 73 Q 73 Q 73
E 74 Nonsolvent –
Y 75 Y 75 Nonsolvent –
C 76 C 76 Nonsolvent –
V 77 V 77
Peptide 8 F 78 Nonsolvent –
L 79 L 79 Nonsolvent –
S 80 S 80 Nonsolvent –
C 81 C 81
I 82 I 82 I 82
A 83 A 83 A 83 Nonsolvent –
M 84 M 84 M 84
M 85 M 85
C 86 Nonplanar –
N 87 N 87 N 87 N 87
E 88 E 88
F 89 F 89
Residues of the potential 6B12 interaction side are identified by peptide screening (column 2). For
the structural analyses, we used the calcium-bound dimeric S100A4 with the PDB ID: 2Q91 [31].
Residues of the dimeric interface of S100A4, involving helix 4-4′ and helix 1-4′, are indicated in
columns 3 and 4, respectively. Nonsolvent–exposed residues and residues that are out of the planar
level of the epitope surface are indicated in column 5. These residues were not accessible for the
antibody binding. The conclusion of the analysis is shown in column 6, indicating a segmented
sequence with potential epitope forming residues of 6B12 antibody.
